{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:57:38Z","timestamp":1777550258559,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treosulfan is an alkylating agent administered before hematopoietic stem cell transplantation. Because pharmacokinetic parameters exhibit interindividual variability, therapeutic drug monitoring may be necessary. In this study, a liquid chromatography\u2013tandem mass spectrometry method for monitoring treosulfan was developed and validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Treosulfan was separated from 25\u2009\u00b5L plasma after protein precipitation with acetonitrile. Treosulfan-D4 was used as the internal standard. Separation was performed using an ACQUITY UPLC \u0399-Class PLUS System (Waters Corporation) coupled with a Xevo TQ-XS Mass Spectrometer (Waters Corporation). Limit of quantification, selectivity, linearity, imprecision, carryover, matrix effect, and stability were validated according to Clinical and Laboratory Standards Institute guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mass-to-charge transitions were treosulfan 296.2\u2009&amp;gt;\u200987.1 and treosulfan-D4 300.2\u2009&amp;gt;\u200991.1. The total run time was 4\u2009minutes. The limit of quantification of treosulfan was 3.13\u2009\u00b5g\/mL. The calibration curve was linear in the 3.13 to 100-\u00b5g\/mL range. The method was adequately selective and without carryover or matrix effect. Treosulfan was stable in plasma for 2\u2009hours at room temperature and for up to 3\u2009days and 1\u2009week when stored at 10\u2009\u00b0C and \u201220\u2009\u00b0C, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our liquid chromatography\u2013tandem mass spectrometry method for measuring treosulfan met Clinical and Laboratory Standards Institute validation requirements and exhibited robust performance, suggesting its utility for therapeutic drug monitoring in clinics treating patients with treosulfan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/labmed\/lmag017","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:24:36Z","timestamp":1773059076000},"source":"Crossref","is-referenced-by-count":0,"title":["A liquid chromatography\u2013tandem mass spectrometry method for therapeutic drug monitoring of treosulfan"],"prefix":"10.1093","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4592-9943","authenticated-orcid":false,"given":"Jeayeon","family":"Ryu","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5897","authenticated-orcid":false,"given":"Sollip","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine , Seoul,","place":["Korea"]},{"name":"University of Ulsan College of Medicine Institute of Digital Healthcare, , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-2593","authenticated-orcid":false,"given":"Sang-Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1651-4415","authenticated-orcid":false,"given":"Sung Han","family":"Kang","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan, College of Medicine , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3956-6397","authenticated-orcid":false,"given":"Woochang","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5792-973X","authenticated-orcid":false,"given":"Sail","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Asan Medical Center, University of Ulsan, College of Medicine , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-4068","authenticated-orcid":false,"given":"Ho Joon","family":"Im","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, Asan Medical Center Children\u2019s Hospital, University of Ulsan, College of Medicine , Seoul,","place":["Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026042813502819100_lmag017-B1","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/ejh.13828","article-title":"A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients","volume":"109","author":"Olivas-Maz\u00f3n","year":"2022","journal-title":"Eur J Haematol"},{"key":"2026042813502819100_lmag017-B2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/ajh.26620","article-title":"Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial","volume":"97","author":"Beelen","year":"2022","journal-title":"Am J Hematol"},{"key":"2026042813502819100_lmag017-B3","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.1182\/blood-2010-10-312082","article-title":"Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience","volume":"117","author":"Slatter","year":"2011","journal-title":"Blood"},{"key":"2026042813502819100_lmag017-B4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/sj.bmt.1704784","article-title":"Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications","volume":"35","author":"Beelen","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2026042813502819100_lmag017-B5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejps.2014.12.010","article-title":"Pharmacokinetics of treosulfan and its active monoepoxide in pediatric patients after intravenous infusion of high-dose treosulfan prior to HSCT","volume":"68","author":"G\u0142\u00f3wka","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"2026042813502819100_lmag017-B6","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/bjh.14960","article-title":"High interpatient variability of treosulfan exposure is associated with early toxicity in paediatric HSCT: a prospective multicentre study","volume":"179","author":"van der Stoep","year":"2017","journal-title":"Br J Haematol"},{"key":"2026042813502819100_lmag017-B7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/cpt.988","article-title":"Pharmacokinetics and pharmacodynamics of treosulfan in patients with thalassemia major undergoing allogeneic hematopoietic stem cell transplantation","volume":"104","author":"Mohanan","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2026042813502819100_lmag017-B8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/cpt.1715","article-title":"Proposed therapeutic range of treosulfan in reduced toxicity pediatric allogeneic hematopoietic stem cell transplant conditioning: results from a prospective trial","volume":"108","author":"Chiesa","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"2026042813502819100_lmag017-B9","doi-asserted-by":"publisher","first-page":"99.e1","DOI":"10.1016\/j.jtct.2021.09.018","article-title":"Impact of treosulfan exposure on early and long-term clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation recipients: a prospective multicenter study","volume":"28","author":"van der Stoep","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026042813502819100_lmag017-B10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jpba.2012.10.005","article-title":"Direct high-performance liquid chromatography method with refractometric detection designed for stability studies of treosulfan and its biologically active epoxy-transformers","volume":"72","author":"G\u0142\u00f3wka","year":"2013","journal-title":"J Pharm Biomed Anal"},{"key":"2026042813502819100_lmag017-B11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/chromsci\/bmv145","article-title":"Development and validation of a high pressure liquid chromatography-UV method for the determination of treosulfan and its epoxy metabolites in human plasma and its application in pharmacokinetic studies","volume":"54","author":"Koyyalamudi","year":"2016","journal-title":"J Chromatogr Sci"},{"key":"2026042813502819100_lmag017-B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jpba.2018.02.049","article-title":"Clinical bioanalysis of treosulfan and its epoxides: The importance of collected blood processing for valid pharmacokinetic results","volume":"153","author":"Roma\u0144ski","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"2026042813502819100_lmag017-B13","volume-title":"CLSI Document C62-Ed2: Liquid Chromatography-Mass Spectrometry Methods","author":"Clinical and Laboratory Standards Institute","year":"2022"},{"key":"2026042813502819100_lmag017-B14","volume-title":"CLSI Document C50-A: Mass Spectrometry in the Clinical Laboratory, General Principles and Guidance, Approved Guideline","author":"Clinical and Laboratory Standards Institute","year":"2007"},{"key":"2026042813502819100_lmag017-B15","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41409-021-01556-8","article-title":"Treosulfan-based conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with non-malignant diseases","volume":"57","author":"Suh","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2026042813502819100_lmag017-B16","author":"National Institutes of Health"},{"key":"2026042813502819100_lmag017-B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1373\/clinchem.2015.238626","article-title":"CLSI C62-A: a new standard for clinical mass spectrometry","volume":"62","author":"Lynch","year":"2016","journal-title":"Clin Chem"},{"key":"2026042813502819100_lmag017-B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.talanta.2014.03.067","article-title":"Rapid and sensitive liquid chromatography-tandem mass spectrometry method for determination of protein-free pro-drug treosulfan and its biologically active monoepoxy-transformer in plasma and brain tissue","volume":"127","author":"Roma\u0144ski","year":"2014","journal-title":"Talanta"},{"key":"2026042813502819100_lmag017-B19","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3390\/cancers14041024","article-title":"Comparison of melphalan combined with treosulfan or busulfan as high-dose chemotherapy before autologous stem cell transplantation in AML","volume":"14","author":"Gurevich","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026042813502819100_lmag017-B20","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1016\/j.xphs.2017.05.033","article-title":"Effect of temperature on the kinetics of the activation of treosulfan and hydrolytic decomposition of its active epoxy derivatives","volume":"106","author":"Roma\u0144ski","year":"2017","journal-title":"J Pharm Sci"},{"key":"2026042813502819100_lmag017-B21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/FTD.0000000000000047","article-title":"Pharmacokinetics of Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation","volume":"36","author":"Ten Brink","year":"2014","journal-title":"Ther Drug Monit"},{"key":"2026042813502819100_lmag017-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2018.04.036","article-title":"Relationship between exposure to treosulfan and its monoepoxytransformer\u2014an insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation","volume":"120","author":"Danielak","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"2026042813502819100_lmag017-B23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jpba.2011.12.021","article-title":"HPLC method for determination of biologically active epoxy-transformers of treosulfan in human plasma: pharmacokinetic application","volume":"62","author":"G\u0142\u00f3wka","year":"2012","journal-title":"J Pharm Biomed Anal"},{"key":"2026042813502819100_lmag017-B24","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/rcm.337","article-title":"Electrospray ionization detection of inherently nonresponsive epoxides by peptide binding","volume":"15","author":"Cech","year":"2001","journal-title":"Rapid Commun Mass Spectrom"},{"key":"2026042813502819100_lmag017-B25","volume-title":"CLSI Document EP15-A3 User Verification of Precision and Estimation Bias, Approved Guideline","author":"Clinical and Laboratory Standards Institute","year":"2014"}],"container-title":["Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/57\/3\/lmag017\/68180941\/lmag017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/labmed\/article-pdf\/57\/3\/lmag017\/68180941\/lmag017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:50:33Z","timestamp":1777398633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/labmed\/article\/doi\/10.1093\/labmed\/lmag017\/8664254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4,3]]}},"URL":"https:\/\/doi.org\/10.1093\/labmed\/lmag017","relation":{},"ISSN":["0007-5027","1943-7730"],"issn-type":[{"value":"0007-5027","type":"print"},{"value":"1943-7730","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,3]]},"article-number":"lmag017"}}